tradingkey.logo

ImmuCell Q4 preliminary sales dip

ReutersJan 8, 2026 9:27 PM


Overview

  • Animal health company's preliminary Q4 sales declined 1.6% yr/yr

  • Domestic sales rose 8.7%, while international sales fell 52.6%


Outlook

  • Company focuses on expanding First Defense capacity after pausing Re-Tain investment

  • ImmuCell plans manufacturing improvements to support First Defense growth targets


Result Drivers

  • TRI-SHIELD GROWTH - Tri-Shield sales increased by 41.3%, driven by new dairy and beef customers, according to CEO Olivier te Boekhorst

  • INTERNATIONAL SALES DECLINE - International sales fell 52.6% due to order timing, per CEO Olivier te Boekhorst

  • STRATEGIC SHIFT - Focus on First Defense after FDA issues with Re-Tain, resulting in a $2.9 mln write-down


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Product Sales

$7.60 mln

Press Release: ID:nGNX2gDkM2

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI